C4 Therapeutics, Inc. CCCC
Set alert
At close · Oct 30
After hours · Oct 30, 4:41 PM ET
- YTD
- +76.44%
- 1 year
- +36.99%
- Open
- 3.23
- Prev close
- 3.30
- Mkt cap
- 414.59M
- Vol
- 2.35M
- Avg vol
- 2.42M
- EPS
- -0.91
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.21
- High
- 3.38
- Forward P/E
- -2.37
- Beta
- 3.06
- Short ratio
- 7.10
- Inst. own
- 91.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 1, 2024
- 50-d avg
- 5.06
- 200-d avg
- 5.96
- 1y target
- 15.00
5D chart
Signals (74)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 3:50 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 3:40 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 1:30 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:10 PM | 1 day ago |
| RSI: Overbought | Oct 30, 12:40 PM | 1 day ago |
| RSI: Overbought | Oct 30, 12:25 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:20 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:15 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 11:25 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:15 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:40 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:05 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:55 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:45 AM | 1 day ago |
| RSI: Overbought | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:40 PM | 2 days ago |
| RSI: Oversold | Oct 29, 2:30 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:40 PM | 2 days ago |
| RSI: Oversold | Oct 29, 1:40 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:00 PM | 2 days ago |
| RSI: Oversold | Oct 29, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 10:05 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 9:45 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 3 days ago |
| RSI: Overbought | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:15 PM | 3 days ago |
| RSI: Overbought | Oct 28, 12:10 PM | 3 days ago |
| RSI: Overbought | Oct 28, 10:35 AM | 3 days ago |
| RSI: Overbought | Oct 28, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 28, 9:55 AM | 3 days ago |
| RSI: Overbought | Oct 28, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:40 PM | 4 days ago |
| RSI: Overbought | Oct 27, 11:20 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:55 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 26, 3:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
News
2 days ago zacks.com
C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
C4 Therapeutics (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 days ago globenewswire.com
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)…
-
3 days ago benzinga.com
Lake Street Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $11
Lake Street analyst Chad Messer initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $11.
-
3 weeks ago benzinga.com
JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10
JP Morgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Price Target of $10.
-
1 month ago benzinga.com
C4 Therapeutics Presents New Biomarker Data From Phase 1 Clinical Trial Of Cemsidomide In Combination With Dexamethasone In Patients With RRMM At 23rd IMS Annual Meeting
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of ActionBiomarker Data from First…
-
1 month ago benzinga.com
C4 Therapeutics To Present New Biomarker Data On Immunomodulatory Effects Of Cemsidomide In Combination With Dexamethasone From Phase 1 Trial For RRMM At IMS Annual Meeting
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the…
-
2 months ago benzinga.com
C4 Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate, Sales $6.641M Beat $4.000M Estimate
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 51.35 percent increase over losses of…
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings…
-
4 months ago benzinga.com
C4 Therapeutics To Present Further Analysis From Fully Enrolled Phase 1 Trial Of Cemsidomide In Combination With Dexamethasone For Treatment Of RRMM At EHA 2026 Congress
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was…
-
5 months ago benzinga.com
Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12
Evercore ISI Group analyst Gavin Clark-Gartner maintains C4 Therapeutics (NASDAQ:CCCC) with a Outperform and raises the price target from $7 to $12.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
5 months ago benzinga.com
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.
5 months ago benzinga.com
Nasdaq Surges Over 1%; Alibaba Shares Gain After Q4 Results
US stocks mixed, Nasdaq up 200 points. Dow down 0.43%, Nasdaq up 0.79%, S&P 500 up 0.27%. Communication services up 1.6%, utilities down 1.4%. Alibaba shares up 6% after reporting mixed Q4 results.…
5 months ago benzinga.com
Vishay Intertechnology, Eos Energy Enterprises, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
Vishay Intertechnology (VSH) stock up 10%, Velo3D (VELO) up 35.5%, VNET (VNET) up 32.5%, C4 Therapeutics (CCCC) up 19.4%, Kingsoft Cloud (KC) up 18.6%, Tower Semiconductor (TSEM) up 17.5%, Nebius…
-
5 months ago benzinga.com
C4 Therapeutics Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $6.152M Beat $3.333M Estimate
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.27) by 25.93 percent. This is a 45.95 percent increase over losses of…
6 months ago benzinga.com
C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies
C4 Therapeutics partners with Roche to develop cancer-fighting DACs. CCCC eligible for $1B+ in milestones plus royalties. See the details.
-
6 months ago benzinga.com
C4 Therapeutics Teams Up With Roche On New Cancer Drug Approach, Secures $20M Upfront, Eyes Over $1B In Future Milestones
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that it has entered into a new…
-
7 months ago benzinga.com
C4 Therapeutics Starts Trial For New Multiple Myeloma Drug Combo
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been…
-
8 months ago benzinga.com
Barclays Maintains Overweight on C4 Therapeutics, Raises Price Target to $7
Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and raises the price target from $5 to $7.
-
8 months ago benzinga.com
C4 Therapeutics Q4 EPS $(0.18) Beats $(0.31) Estimate, Sales $11.016M Beat $6.460M Estimate
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.31) by 41.37 percent. This is a 63.27 percent increase over losses of…
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
8 months ago benzinga.com
Brookline Capital Maintains Buy on C4 Therapeutics, Raises Price Target to $30
Brookline Capital analyst Leah Rush maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and raises the price target from $20 to $30.
-
8 months ago benzinga.com
C4 Therapeutics Doses First Patient In Phase 2 MOMENTUM Trial Of Oral Cemsidomide With Dexamethasone For Relapsed Refractory Multiple Myeloma
Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026
11 months ago benzinga.com
This Coca-Cola Femsa Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday
This Coca-Cola Femsa Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday
11 months ago benzinga.com
This Cloudflare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
This Cloudflare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
2 years ago benzinga.com
Capital One Financial To Acquire Discover, Joins SSR Mining And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures trading lower by around 50 points on Tuesday.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 647 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 406 companies made new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 283 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 179 companies reached new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 104 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 185 companies achieved new lows for the year.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 220 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 95 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 89 stocks made new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 469 companies hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 337 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 479 stocks made new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 497 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 135 companies reached new 52-week lows.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023
-
3 years ago benzinga.com
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
-
4 years ago benzinga.com
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 951 companies hit new 52-week lows.